---
title: "PERRIGO Co plc 2026: Revenue $1.02B, EPS $0.53— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294998560.md"
description: "Perrigo Co plc reported Q2 2026 results with net sales of $1.02B, a 3.2% YoY decline, and diluted EPS of $0.53, marking a swing to positive net income of $74.5M from a loss in the prior year. Revenue was impacted by soft consumption and lower inventory, though store-brand strength and brand momentum for Opill® and Compeed® provided support. The company completed workforce reductions and operational enhancements while reviewing its infant formula business."
datetime: "2026-08-05T17:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294998560.md)
  - [en](https://longbridge.com/en/news/294998560.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294998560.md)
generator: "portal-rs"
---

# PERRIGO Co plc 2026: Revenue $1.02B, EPS $0.53— 10-Q Summary

PERRIGO Co plc reported results for the 2026 quarter with net sales of $1.02B and diluted earnings per share of $0.53, marking a revenue decline versus the prior year and a swing to positive net income of $74.5M — 10-Q Summary.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$1.02B

$1.06B

(3.2%)

Net income²

$74.5M

($8.4M)

986.9%

Diluted EPS³

$0.53

($0.06)

983.3%

*¹ Reported as “Net sales”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted earnings (loss) per share”.*

**Business Highlights**

-   Revenue trend: Net sales declined roughly 3–5% year-to-date, driven by soft consumption and lower retailer inventory levels, primarily in Self Care.
-   Channel & mix: Continued store-brand strength offset by lower seasonal cough/cold demand and the Dermacosmetics divestiture, which reduced sales mix.
-   Brand momentum: Opill®, ellaOne® and Compeed® gained share; Infant Formula experienced contract shipment growth despite prior production challenges.
-   Operations: Completed Supply Chain Reinvention and Project Energize targets and launched an Operational Enhancement program to reduce costs and cut roughly 7% of the workforce.
-   Quality & regulatory: Completed infant formula plant resets, strengthened quality assurance protocols after FDA interactions, and initiated a strategic review of the infant formula business.

Original SEC Filing: PERRIGO Co plc \[ PRGO \] - 10-Q - Aug. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md)

## Related News & Research

- [Perrigo executives meet investors at Barclays Global Consumer Conference](https://longbridge.com/en/news/297186381.md)
- [Perrigo’s Q2 Return To Profit Amid Lower Sales Might Change The Case For Investing In PRGO](https://longbridge.com/en/news/296008507.md)
- [Michael Burry Says He 'Flipped' His Alibaba Stock into JD and Won't Be Flipping Back — Hong Kong-Listed Stock Falls Nearly 10% on $10B Raise](https://longbridge.com/en/news/296735167.md)
- [Sky Harbour prices 1,000,000-share registered direct offering at $10 per share](https://longbridge.com/en/news/297083252.md)
- [Check-Cap closes USD 10 million follow-on offering at USD 6.5 per share](https://longbridge.com/en/news/297327530.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**